---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-26-000049"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2026-08-05T20:14:24+00:00"
generated_at: "2026-08-05T20:15:12.041739+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcutis Q2 net income $15M, revenue $129.9M (+59% YoY); raises FY guidance; CCO resigns

## Summary
- Q2 net product revenue $129.9M (+59% YoY, +23% QoQ); net income $15.0M ($0.11 EPS) vs net loss $15.9M in Q2 2025.
- Raised FY2026 net product sales guidance to $525M-$540M from $480M-$495M.
- FDA approved ZORYVE cream 0.3% for children aged 2+; sNDA accepted for ZORYVE cream 0.05% in infants (PDUFA Feb 23, 2027).
- CCO L. Todd Edwards resigns effective Aug 21; Robert Lisicki appointed interim CCO (base $555K, equity grants).
- Positive operating cash flow $12.6M; cash $238.9M.

## SEC filing metadata
- accession: 0001787306-26-000049
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2026-08-05T20:14:24+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/0001787306-26-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/arqt-20260731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-26-000049
- JSON: https://secwatch.observer/filing/0001787306-26-000049.json
- Plain text: https://secwatch.observer/filing/0001787306-26-000049.txt

## Key facts
- Executive change
  Robert Lisicki was appointed as interim chief commercial officer at Arcutis Biotherapeutics, Inc..
  - Action: appointed
  - Role: interim chief commercial officer
  source text: has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards’ departure from the Company on August 21, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/0001787306-26-000049-index.htm
- Executive change
  L. Todd Edwards resigned as chief commercial officer at Arcutis Biotherapeutics, Inc..
  - Action: resigned
  - Role: chief commercial officer
  source text: On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/0001787306-26-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.